Editas Medicine Inc $ 30.94 -1.86 (-5.66%)
Volume:
616,591
Avg Vol (1m):
896,871
Market Cap $:
1.93 Bil
Enterprise Value $:
1.36 Bil
P/E (TTM):
0.00
P/B:
4.49
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 20.79 | ||
| Equity-to-Asset | 0.65 | ||
| Debt-to-Equity | 0.07 | ||
| Debt-to-EBITDA | -0.21 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 4.4 | ||
| Beneish M-Score | 106.1 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -466.09 | ||
| Net Margin % | -404.88 | ||
| ROE % | -49.75 | ||
| ROA % | -27.98 | ||
| ROC (Joel Greenblatt) % | -394.81 | ||
| 3-Year Revenue Growth Rate | 29.8 | ||
| 3-Year EBITDA Growth Rate | 2.5 | ||
| 3-Year EPS without NRI Growth Rate | 3.9 |
EDIT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.49 | ||
| PS Ratio | 50.64 | ||
| EV-to-EBIT | -9.88 | ||
| EV-to-EBITDA | -10.08 | ||
| EV-to-Revenue | 41.6 | ||
| Current Ratio | 8.95 | ||
| Quick Ratio | 8.95 | ||
| Days Sales Outstanding | 20.88 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.5 | ||
| Earnings Yield (Greenblatt) % | -10.12 |